Kim, Hyun Yul; Jung, Youn Joo; Lee, Sang Hyup; Jung, Hyuk Jae; Pak, Kyoungjune
Oncology
2017NA ; 92 ( 5 ) :264-268.
PMID : 28132057
ÀúÀÚ »ó¼¼Á¤º¸
Kim, Hyun Yul -
Jung, Youn Joo -
Lee, Sang Hyup -
Jung, Hyuk Jae -
Pak, Kyoungjune -
ABSTRACT
OBJECTIVE: Preclinical studies have proved that beta-blocking agents inhibit several pathways for breast cancer progression and metastasis. We aimed to evaluate the association between beta-blocker use and prognosis of breast cancer.
METHODS: A systematic search for studies from MEDLINE and EMBASE (inception to March 2014) was performed using the keywords "breast cancer" and "beta-blocker." In 2 groups of breast cancer patients (beta-blocker users and non-beta-blocker users), overall deaths (ODs), cancer-specific deaths (CSDs), and recurrences were compared.
RESULTS: Six studies including 18,118 patients were eligible for this analysis. Two studies with 3,139 patients were included in the analysis of ODs. The random-effects model showed no significant difference in ODs between beta-blocker users and non-beta-blocker users (odds ratio [OR] 0.87, 95% confidence interval [CI] 0.50-1.52, p = 0.49). Four studies with 13,782 patients were included in the measurement of CSDs. The difference in CSDs between beta-blocker users and non-beta-blocker users was not significant using the fixed-effect model (OR 0.93, 95% CI 0.82-1.06, p = 0.29). Three studies with 3,923 patients were included in the calculation of recurrences. Overall, beta-blockers did not affect the incidence of recurrence (OR 0.70, 95% CI 0.25-1.95, p = 0.49). CONCLUSION: Beta-blockers were not beneficial regarding ODs, CSDs, or recurrences. Further studies are needed to evaluate the associations between the effects of beta-blockers and subtypes of breast cancer. CI - ??2017 S. Karger AG, Basel.
Adrenergic beta-Antagonists/*therapeutic use; Breast Neoplasms/complications/*drug therapy/mortality; Disease Progression; Female; Humans; Hypertension/complications/*drug therapy; Incidence; Neoplasm Metastasis/prevention & control; Neoplasm Recurrence, Local/prevention & control; Survival Analysis; Treatment Outcome
MESH
Adrenergic beta-Antagonists/*therapeutic use, Breast Neoplasms/complications/*drug therapy/mortality, Disease Progression, Female, Humans, Hypertension/complications/*drug therapy, Incidence, Neoplasm Metastasis/prevention & control, Neoplasm Recurrence, Local/prevention & control, Survival Analysis, Treatment Outcome
¸µÅ©